The Next Investors portfolio covers special opportunities across a broad range of sectors at an early stage of growth with strong management. Seeking 1000% plus returns across a range of medium and long term holds.
Finfeed if following on from one of Australia’s most successful biotech and life sciences fund managers to select and invest in early to mid-stage ASX listed biotechs
Shorter term positions in small early stage ASX exploration companies with high potential, near term price catalysts.
The Next Investors portfolio covers special opportunities across a broad range of sectors at an early stage of growth with strong management. Seeking 1000% plus returns across a range of medium and long term holds.
Returns from Initial Entry
77%
Returns from Initial Entry
4%
Returns from Initial Entry
-7%
Returns from Initial Entry
36%
Returns from Initial Entry
-5%
Returns from Initial Entry
35%
Returns from Initial Entry
-28%
Returns from Initial Entry
-30%
Returns from Initial Entry
23%
Returns from Initial Entry
-10%
Returns from Initial Entry
-28%
Returns from Initial Entry
10%
Returns from Initial Entry
-16%
Returns from Initial Entry
-46%
Returns from Initial Entry
308%
Returns from Initial Entry
-26%
Returns from Initial Entry
-63%
Returns from Initial Entry
-77%
Returns from Initial Entry
-5%
Returns from Initial Entry
16%
Returns from Initial Entry
-66%
Returns from Initial Entry
79%
Returns from Initial Entry
-34%
Returns from Initial Entry
-41%
Returns from Initial Entry
624%
Returns from Initial Entry
333%
Returns from Initial Entry
244%
Returns from Initial Entry
140%
Returns from Initial Entry
11%
Returns from Initial Entry
65%
Returns from Initial Entry
-38%
Returns from Initial Entry
-38%
Returns from Initial Entry
3630%
Returns from Initial Entry
-63%
Returns from Initial Entry
285%
Returns from Initial Entry
54%
The past performance is not and should not be taken as an indication of future performance. Caution should be exercised in assessing past performance. This product, like all other financial products, is subject to market forces and unpredictable events that may adversely affect future performance.
The Initial Entry Price is calculated by taking the Volume Weighted Average Price (VWAP)
for Shares Acquired by S3 Consortium and Associated Entities after 1 Jan 2019 measured
from the date that the stock is announced in a Portfolio.
S3 Consortium and our Associated Entities share our Investment journey over time through our public Portfolios.
Occasionally we Invest in seed and pre-IPO capital raising which are factored into our Initial Entry Price.
For more definitions regarding our Portfolio please
read our FAQ page.